QR019, Rb

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human p16
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic, nuclear
Kontrolle:Cervical carcinoma
Synonyme:CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16, cyclin-dependent kinase inhibitor 2A, cyclin dependent kinase inhibitor 2A, Genes, p16
Verfügbar in folgenden Ländern:worldwide

p16 is a protein that slows cell division by slowing the progression of the cell cycle from the G1 phase to the S phase, thereby acting as a tumor suppressor. A deletion in this gene can result in insufficient or non-functional p16, accelerating the cell cycle and resulting in many types of cancer. p16 can be used as a biomarker to improve the histological diagnostic accuracy of grade 3 cervical intraepithelial neoplasia (CIN). p16 is also implicated in the prevention of melanoma, oropharyngeal squamous cell carcinoma, cervical cancer, vulvar cancer and esophageal cancer.